How to Get Your Insurance to Cover Semaglutide: Strategies That Actually Worked in 2026

Where Does Insurance Coverage for Semaglutide Stand in 2026?

Insurance coverage for GLP-1 medications has improved significantly over the past two years, but it is still inconsistent and often frustrating to navigate.

The big picture: most commercial insurance plans cover semaglutide (as Ozempic) for type 2 diabetes without much hassle. Coverage for weight management (as Wegovy) is where things get complicated. Many plans still classify anti-obesity medications as "lifestyle" drugs and exclude them entirely.

What changed recently:

• Medicare Part D coverage (2026): CMS negotiated a $245/month price for injectable GLP-1s. This was the single largest expansion of GLP-1 access in the US. Eligible Medicare beneficiaries with a BMI of 30+ (or 27+ with a comorbid condition) can now access brand-name Wegovy through their Part D plan.
• Employer plan expansion: Several large employers added GLP-1 coverage in 2025-2026, including some that had previously excluded weight management drugs. The SELECT trial data (20% reduction in major cardiovascular events; NEJM 2023, DOI: 10.1056/NEJMoa2307563) gave employers and insurers clinical justification to cover these drugs for cardiovascular risk reduction, not just weight loss.
• State mandates: A handful of states have passed or are considering legislation requiring insurers to cover FDA-approved anti-obesity medications. Check your state's insurance department for current requirements.

Despite these improvements, denial rates remain high. Many patients report initial denial rates above 40% for weight-management GLP-1 prescriptions, with appeals adding 30-90 days to the process.

How Do You Find Out if Your Plan Covers Semaglutide?

Before your doctor submits anything, do your own research. This saves weeks of back-and-forth.

1. Check your formulary online. Log into your insurer's member portal and search the drug formulary for "semaglutide," "Ozempic," and "Wegovy." The formulary tells you which tier the drug sits on and whether prior authorization is required. If neither drug appears on the formulary, your plan likely excludes it.
2. Call the number on your insurance card. Ask specifically: "Does my plan cover Wegovy for weight management?" and "Does my plan cover Ozempic for type 2 diabetes?" Get the representative's name and a reference number for the call. The answers to these two questions are often different.
3. Request the prior authorization criteria in writing. Ask your insurer to send you the clinical criteria for GLP-1 approval. This document tells you exactly what your doctor needs to document. Having it in advance lets you and your doctor prepare the strongest possible submission.
4. Check for exclusions. Some plans have a blanket exclusion for "anti-obesity medications" or "weight management drugs." If your plan has this exclusion, prior authorization will be denied automatically. Your options then are appealing (harder but possible), switching plans at open enrollment, or going the compounded or cash-pay route.

Which Diagnosis Codes Improve Your Chances?

The diagnosis codes (ICD-10) your doctor submits with the prior authorization make a measurable difference in approval rates. Here are the codes that matter:

The strategy: your doctor should list every applicable diagnosis, not just obesity. A prior authorization submission with E66.01 + I10 + E78.5 + G47.33 tells a much stronger medical necessity story than E66.01 alone. Insurers approve cases where the medication addresses multiple conditions, not just weight.

Talk to your doctor about which of these conditions apply to you. If you have lab work showing elevated A1C, cholesterol, or liver enzymes, include those results with the prior authorization.

What Does the Prior Authorization Process Look Like?

Prior authorization is your insurer's way of making sure the prescription meets their clinical criteria before they agree to pay for it. For a detailed walkthrough, see our prior authorization step-by-step guide. Here is the summary:

1. Your doctor submits the PA form. This includes your diagnosis codes, BMI, relevant lab work, prior treatment history, and a clinical justification for why semaglutide is medically necessary.
2. The insurer reviews it. Turnaround is typically 2-15 business days, though some plans offer expedited review in 24-72 hours for urgent cases.
3. You get approved, denied, or asked for more information. If approved, your pharmacy can fill the prescription. If denied, you have the right to appeal. If they ask for more documentation, your doctor supplies it and the clock restarts.

Common reasons for PA denial:

• BMI does not meet the plan's threshold (usually 30+, or 27+ with comorbidity)
• No documentation of prior treatment attempts (step therapy not satisfied)
• Missing lab work or incomplete medical records
• Plan excludes anti-obesity medications entirely
• Wrong drug requested (e.g., Wegovy for a plan that only covers Ozempic for diabetes)

What Is Step Therapy and How Do You Handle It?

Step therapy, sometimes called "fail-first," is a requirement that you try cheaper medications before your insurer will cover semaglutide. This is one of the most common barriers to GLP-1 coverage.

Typical step therapy requirements for semaglutide:

• Step 1: Lifestyle modification (diet and exercise) documented for 3-6 months
• Step 2: Trial of a lower-cost weight loss medication (phentermine, Contrave/naltrexone-bupropion, or orlistat) for 3-6 months
• Step 3: If steps 1 and 2 fail to produce adequate results, semaglutide is approved

The practical advice: if you have not tried other treatments yet, your fastest path to semaglutide coverage may be to start the step therapy process now. Ask your doctor to prescribe phentermine or Contrave, document the results (or lack thereof) carefully for 3-6 months, and then resubmit for semaglutide with that documentation.

If you have already tried other approaches and they did not work, make sure your medical records reflect that. Dig up old prescription records, weight logs, and any documentation of supervised diet programs. Your doctor can reference this history in the prior authorization to satisfy step therapy without starting over.

Some states have passed step therapy reform laws that limit how long insurers can require you to stay on a medication that is not working. Check whether your state has these protections.

How to Appeal a Denial and Improve Your Odds

If your prior authorization gets denied, you have the legal right to appeal. And you should, because the numbers favor you: the Government Accountability Office found that 39-59% of internal appeals succeed.

The appeal process typically has two levels:

Internal appeal (Level 1): You ask your insurer to reconsider. This is where most cases get resolved. You have 180 days from the denial to file in most states.

External review (Level 2): If the internal appeal fails, you can request an independent external review. A physician who does not work for your insurer reviews the case. Under the ACA, your insurer is required to offer this option.

What makes a strong appeal

The appeals that succeed share a few characteristics:

• A letter of medical necessity from your doctor. This is the single most important document. It should explain why semaglutide is medically necessary for your specific case, reference your diagnosis codes and comorbidities, cite the clinical trial evidence (STEP 1 showed 14.9% mean weight loss, NEJM 2021; SELECT showed 20% cardiovascular risk reduction, NEJM 2023), and explain why alternative treatments are insufficient or have already failed.
• Complete medical records. Lab work, BMI history, documentation of prior treatment attempts, specialist notes. The more thorough the file, the harder it is to deny.
• Peer-to-peer review request. Your doctor can request a phone call with the insurer's reviewing physician to discuss your case directly. This is often more effective than sending paper documents back and forth.
• Specificity about the denial reason. Address the exact reason for denial point by point. If they said BMI was too low, provide the measurements. If they said step therapy was not completed, provide the documentation. Do not write a general plea. Respond to their specific objections.

Tips by Insurance Carrier

Coverage policies change frequently, so verify current details with your specific plan. These are general patterns patients have reported as of early 2026:

UnitedHealthcare: Many employer-sponsored UHC plans cover Wegovy with prior authorization. Step therapy is common. The PA process typically takes 5-10 business days. Some UHC Medicare Advantage plans have added GLP-1 coverage following the CMS negotiation.

Blue Cross Blue Shield: Varies enormously by state affiliate. Some BCBS plans have added Wegovy coverage specifically for patients with cardiovascular risk factors, citing the SELECT trial. Others still exclude it. Check your state's BCBS formulary.

Aetna: Aetna has been relatively progressive on GLP-1 coverage. Many Aetna plans cover Wegovy with PA and step therapy. The step therapy requirement often includes a 3-month trial of lifestyle modification.

Cigna: Coverage varies by plan. Cigna has moved some GLP-1s to preferred formulary tiers in 2025-2026, reducing copays for covered patients. Prior authorization is standard.

Kaiser Permanente: Kaiser's integrated model means your Kaiser doctor handles PA internally. Coverage for weight management GLP-1s has expanded in several Kaiser regions. Ask your PCP directly about current formulary status.

Tricare: Tricare covers Ozempic for diabetes. Wegovy coverage for weight management has been added for some Tricare plans in 2025-2026 but is not universal. Check your specific Tricare plan benefit.

What About Medicare and Medicaid?

Medicare Part D: The negotiated $245/month price for injectable GLP-1s is the biggest access improvement for seniors in 2026. Eligible beneficiaries need a BMI of 30+ (or 27+ with a comorbid condition) and a prescription from their provider. Not all Part D plans have implemented this coverage identically, so check with your specific plan.

Medicaid: Coverage varies by state. As of March 2026, roughly half of state Medicaid programs cover GLP-1 medications for at least one indication (diabetes), with a growing number adding weight management coverage. States that have added or expanded Medicaid GLP-1 coverage recently include California, New York, and several others. Check your state's Medicaid formulary for current status.

If Insurance Says No: Your Other Options

Not everyone wins the insurance battle, and some plans simply exclude anti-obesity medications. If that is your situation, here are the practical alternatives:

• Compounded semaglutide: $129-$349/month through licensed telehealth providers. No insurance needed. FormBlends offers compounded semaglutide at $199/month all-inclusive. See our pricing comparison guide.
• HSA/FSA: Pay with pre-tax dollars for a 20-35% effective discount. Works for both brand and compounded semaglutide. Details in our HSA/FSA guide.
• Novo Nordisk savings card: If you have commercial insurance that covers Wegovy but with a high copay, the manufacturer savings card can reduce your cost to $0-$25/month for up to 13 fills.
• Switch plans at open enrollment: If your current plan excludes GLP-1s, this is worth considering during your next enrollment period. Look for plans that list Wegovy on their formulary before enrolling.
• Diagnosis-based approach: If your plan covers Ozempic for diabetes but not Wegovy for weight loss, and you have pre-diabetes or type 2 diabetes, your doctor may be able to prescribe Ozempic instead. This is a conversation between you and your physician about the most appropriate medication for your conditions.

What the Community Reports

Insurance coverage threads are among the most emotional discussions in GLP-1 communities. The recurring themes from r/Semaglutide, r/Ozempic, and r/WegovyWeightLoss:

• Patients who succeed at appeals almost always had a doctor willing to write a detailed letter of medical necessity and do a peer-to-peer review. The doctor's involvement is the single biggest predictor of appeal success.
• Many patients report being denied initially but approved on the first appeal, suggesting that the initial denial is sometimes a screening mechanism rather than a final decision.
• The step therapy requirement is the most common frustration. Patients describe spending 3-6 months on medications they knew would not work, just to satisfy the insurer's checklist.
• Some patients found success by having their doctor resubmit with additional diagnosis codes (adding hypertension, sleep apnea, or PCOS to the obesity code) rather than appealing the original denial.
• Patients who switched from a denied brand-name prescription to compounded semaglutide overwhelmingly report satisfaction with the decision, despite initial nervousness about compounded medications.

Source: Community discussions in r/Semaglutide, r/Ozempic, r/WegovyWeightLoss (aggregated themes)

Frequently Asked Questions